Jean Christophe Eymard

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Gwénaëlle Gravis, Patricia Marino, Florence Joly et al. · European Journal of Cancer · 2014 · 66 citations

Medicine, Oncology, Urology +9

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

Pernelle Lavaud, Gwénaëlle Gravis, Stéphanie Foulon et al. · European Urology · 2017 · 63 citations

Medicine, Oncology, Urology +17

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Sylvain Ladoire, Jean Christophe Eymard, Sylvie Zanetta et al. · PubMed · 2010 · 41 citations

Medicine, Oncology, Pharmacology +17

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer

Thierry Petit, Abdellatif Benider, Alejandro Yovine et al. · Anti-Cancer Drugs · 2006 · 24 citations

Medicine, Oncology, Pharmacotherapy +17